Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175674PMC
http://dx.doi.org/10.1002/jha2.217DOI Listing

Publication Analysis

Top Keywords

asymptomatic leishmaniasis
4
leishmaniasis patient
4
patient relapsed
4
relapsed multiple
4
multiple myeloma
4
asymptomatic
1
patient
1
relapsed
1
multiple
1
myeloma
1

Similar Publications

Article Synopsis
  • - The World Health Organization has identified Thailand as a hotspot for leishmaniasis, with increasing cases of the disease caused by two local species leading to various clinical presentations.
  • - A new duplex TaqMan quantitative PCR assay was developed to diagnose and differentiate between the two species causing visceral and cutaneous leishmaniasis, utilizing specific primers and probes for accurate detection.
  • - The assay demonstrated excellent diagnostic performance, achieving 100% sensitivity and specificity, and proving to be a rapid and cost-effective solution for detecting these parasitic infections in clinical and environmental samples.
View Article and Find Full Text PDF

Background: Detection of infection with Mycobacterium leprae allows timely prophylactic treatment, thereby reducing transmission as well as the risk of permanent, leprosy-associated nerve damage. However, since there is no worldwide-implemented standard test for M. leprae infection, detection of infection in asymptomatic individuals remains a major challenge for control programs in endemic areas.

View Article and Find Full Text PDF

Background: Targeted preventive strategies in persons living with HIV (PLWH) require markers to predict visceral leishmaniasis (VL). We conducted a longitudinal study in a HIV-cohort in VL-endemic North-West Ethiopia to 1) describe the pattern of Leishmania markers preceding VL; 2) identify Leishmania markers predictive of VL; 3) develop a clinical management algorithm according to predicted VL risk levels.

Methods: The PreLeisH study followed 490 adult PLWH free of VL at enrolment for up to two years (2017-2021).

View Article and Find Full Text PDF

Visceral leishmaniasis (VL) is the third most severe infectious parasitic disease and is caused by the protozoan parasite . To control the spread of the disease in endemic areas where the asymptomatic patients act as reservoirs as well as in nonendemic areas, an effective vaccine is indispensable. In this direction, we have developed three chimeric proteins by the combination of three already known Th1 stimulatory leishmanial antigens, i.

View Article and Find Full Text PDF

Atypical cutaneous leishmaniasis: a new challenge to VL elimination in South-East Asia.

Front Cell Infect Microbiol

November 2024

Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada.

Visceral leishmaniasis (VL) caused by in South-East Asian endemic countries including India, Nepal and Bangladesh has been the primary focus of the ongoing VL elimination program. With a major reduction in VL cases resulting from the elimination program during the last two decades, the efforts are now focused on the challenges posed by potential reservoirs within the asymptomatic cases, HIV-co-infection VL cases and Post Kala-azar Dermal Leishmaniasis (PKDL) cases that continue to sustain the parasite transmission cycle in known and newer endemic zones. This article brings attention to a new potential parasite reservoir in the form of atypical cutaneous leishmaniasis (ACL) cases caused by novel genetic variants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!